Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
Related Content
-
Barriers and Facilitators to Care for Individuals With Sickle Cell Disease in Central North Carolina: The Emergency ...Background: Sickle cell disease (SCD) i...
-
How Sickle Cell Anaemia Impacts Families and How We Can Helphttps://www.youtube.com/watch?v=5GUiuXQ9...
-
Women with Sickle Cell Disease and Postpartum Care: What to Know After Delivering Your BabyPostpartum care is health care you get a...
-
Alecia Nero, MDA hematology specialist at UT Southweste...
-
Toronto Neuroscientist Getting Closer to Tailored Treatments for Chronic PainDaily tasks most people don't think too ...
-
Brandon Hardesty, MDBrandon Hardesty serves as an IHTC adult...
-
Sickle Cell Disease Association of America Michigan Chapter, Inc.The vision of Sickle Cell Disease Associ...
+myBinder